Study Title

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Study Details

Description:

Patients will be treated with GD2-SADA and 177Lu-DOTA to study the safety and how well participants tolerate the treatment.

Sponsor:

Y-mAbs Therapeutics, Inc.

Government Study Link:

NCT05130255 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468